Romiplostim

Drug Profile

Romiplostim

Alternative Names: AMG-531; Nplate; Romiplate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen
  • Class Carrier proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Thrombopoietin receptor agonists; Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Immune thrombocytopenic purpura
  • Phase II/III Aplastic anaemia
  • Phase II Thrombocytopenia
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 22 Jun 2017 Interim efficacy and adverse event data from a phase III trial in Immune thrombocytopenic purpura presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 01 Jun 2017 Kyowa Hakko Kirin China Pharmaceutical completes a phase III trial in Immune thrombocytopenic purpura in China (SC) (NCT02868099)
  • 14 Feb 2017 Amgen has patent protection for romiplostim in USA and European Union (Amgen 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top